Cue Biopharma Announces Appointment of Colin Sandercock as Senior Vice President and General Counsel
(World News Science)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue BiopharmaTM, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced the appointment of Colin Sandercock as Senior Vice President and General Counsel. Sandercock brings more than 30 years of experience advising life sciences companies on a broad range of legal matters, including domestic and international patent litig ......